RET fusion as a treatable resistance mechanism in EGFR mutation lung cancer - A case report

被引：0
|
作者：
Athipatla, Vivek [1 ]
Hall, Ashley [2 ]
Dahiya, Marta [2 ]
Narra, Kalyani [2 ]
机构：
[1] Carroll Med Acad, Southlake, TX USA
[2] JPS Oncol & Infus Ctr, Ft Worth, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.93
引用
收藏
页码：E41 / E41
页数：1
相关论文
共 50 条
  • [1] NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature
    Romagnolo, Alberto P.
    Hino, Christopher
    Mirshahidi, Saied
    Chase, Kristina
    Mirshahidi, Hamid
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 10
  • [2] CCDC6-RET Fusion as a Mechanism of Acquired EGFR Resistance
    Desai, A.
    Segal, J.
    Szeto, L.
    Vokes, E. E.
    Patel, J. D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1573 - S1573
  • [3] The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma
    Zhu, You-cai
    Wang, Wen-xian
    Zhang, Qu-xia
    Xu, Chun-wei
    Zhuang, Wu
    Du, Kai-qi
    Chen, Gang
    Lv, Tang-feng
    Song, Yong
    CLINICAL LUNG CANCER, 2019, 20 (01) : E73 - E76
  • [4] Experience with Erlotinib in Lung Adenocarcinoma Harboring a Coexisting KIF5B-RET Fusion Gene and EGFR Mutation Report of a Rare Case
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Taguchi, Kenichi
    Toyozawa, Ryo
    Inamasu, Eiko
    Toyokawa, Gouji
    Yoshida, Tsukihisa
    Shiraishi, Yoshimasa
    Takenaka, Tomoyoshi
    Yamaguchi, Masafumi
    Ushijima, Chie
    Seto, Takashi
    Takeo, Sadanori
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (05) : E37 - E39
  • [5] A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report
    Liang, Ping
    Qi, Lijuan
    Guo, Taiyan
    You, Xia
    Cui, Chengxu
    LUNG CANCER, 2021, 152 : 193 - 195
  • [6] Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET- Rearranged Lung Adenocarcinoma: A Case Report
    Gazeu, Alexia
    Aubert, Mylena
    Pissaloux, Daniel
    Lantuejoul, Sylvie
    Perol, Maurice
    Ikhlef, Nadia
    Bouhamama, Amine
    Franceschi, Tatiana
    Swalduz, Aurelie
    CLINICAL LUNG CANCER, 2022, 24 (01) : 72 - 75
  • [7] A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report
    Sun, Yanwei
    Pei, Lina
    Luo, Ningning
    Chen, Dongsheng
    Meng, Lingxin
    ONCOTARGETS AND THERAPY, 2020, 13 : 11177 - 11181
  • [8] Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report
    He, Cheng
    Wang, Yong
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (02)
  • [9] OsimertinibAcquired resistance in EGFR-mutated lung cancer: case report
    Reactions Weekly, 2021, 1836 (1) : 619 - 619
  • [10] Emergence of CCDC6-RET Fusion with Maintained EGFR T790M Mutation After Resistance to Osimertinib in NSCLC: A Case Report
    Guo, Y.
    Guo, R.
    Cheng, H.
    Wang, H.
    Lou, F.
    Cao, S.
    Guo, W.
    Song, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S846 - S846
12345